The FDA has found, in its own direct comparison, that generic Budeprion XL 300 mg is not therapeutically equivalent to brand-name Wellbutrin XL 300 mg. The agency is therefore changing its bioequivalence recommendations for extended-release bupropion products.
No takes yet. Share an insight, caveat, or question.
Woodcock et al. (2012) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: